Dupilumab: An emerging therapy in allergic fungal rhinosinusitis()

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulkhi, Adeeb A., Mirza, Ahmad A., Aburiziza, Abdullah J., Marglani, Osama A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023893/
https://www.ncbi.nlm.nih.gov/pubmed/35497650
http://dx.doi.org/10.1016/j.waojou.2022.100638
Descripción
Sumario:Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.

Ejemplares similares